Joint lubricant could signal canine OAOctober 15, 2020Canine and human osteoarthritis (OA) might soon see improved diagnostics and treatment methods.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Animal Pain Awareness Month kicks offSeptember 2, 2020Animals are good at hiding pain, which is why it’s important for veterinarians to educate clients on tell-tale signs that all is not well with their pet.
Chronic pain in dogs: The gift that keeps on givingAugust 28, 2020Pain in animals is what we (humans) say it is. There is tremendous variability among both patients and observers.
Is glucosamine effective for treating osteoarthritis?July 27, 2020As trained members of a scientific profession, it is best to understand why anecdotal evidence supporting the use of glucosamine is not a sufficient justification for recommending or selling it to client.
Managing canine osteoarthritis in all stages and agesJune 2, 2020Evidence shows the most predictably successful method to managing OA in dogs is a proactive approach emphasizing prevention.
Managing OA with anti-NGF therapyNovember 22, 2019It is clear to any practicing veterinarian there is a very limited toolbox when it comes to effective treatments for osteoarthritis (OA) pain in dogs and cats. The need, however, is quite apparent.
Dietary supplements and osteoarthritisNovember 21, 2019A multimodal approach to the management of OA has been recommended to target different pain receptors and attempt to control inflammation within the joints.
Elanco guide helps owners spot OAOctober 10, 2019Veterinarians are now better equipped to educate clients on canine osteoarthritis (OA), thanks to Elanco Animal Health.
Osteoarthritis in pets on the rise alongside obesity epidemicJune 25, 2019The prevalence of osteoarthritis (OA) in pets has skyrocketed in the past decade, with the condition seeing a 66 percent increase in dogs and a 150 percent increase in cats.
Penn Vet to study hemp-based canine supplementMay 28, 2019A trial at the University of Pennsylvania School of Veterinary Medicine (Penn Vet) will be looking at the effectiveness of a hemp-based supplement to relieve symptoms of canine joint immobility. Approximately 60 dogs who are suffering from inflammation secondary to osteoarthritis will be split into three groups. One group will receive Mobility, which was developed by Dixie Brands' subsidiary Therabis. The second group will receive CBD, and the last group will receive a placebo. The dogs will then be studied to see which group achieves a better outcome. "We are honored to have a Therabis product selected by the world-renowned experts at Penn Vet for their first major study of the effects of natural hemp oil to reduce joint pain in dogs," says Therabis cofounder, Stephen M. Katz, DVM. "Our experience in my clinic has shown cannabidiol (CBD) is an effective treatment in reducing inflammatory response. We have a passion for improving dogs' quality of life, and we look forward to learning all we can about therapeutic methods to achieve this." Physical tests will be used to measure the effectiveness of the products, mostly focusing on the front leg joints. Results are expected in approximately 12 months.
